Bristol-Myers Squibb France BMS recently announced divesting from their facilities in Epernon and Meymac but at the same time reinforcing manufacturing in Agen. Could you speak to strategy of this restructuring within France and what it means for the future? In the larger context of the industry, we are at a crossroads where…
Meizler Biopharma There is little publicly available information on your personal history and the founding of Meizler. Can you share that story for our readers? Everybody has a story – unless they’re second generation, of course! I am an architect by training. Before entering the pharmaceutical industry I owned an engineering and…
GlaxoSmithKline Colombia Michael Sean Reilly: General Manager for Pharmaceuticals Juan Carlos Berbessi: Medical Director Maria del Pilar Rubio: Medical Manager for Vaccines Gustavo Zapata: Finance Director Juan Pablo Restrepo: Legal Affairs Manager What is the strategic role and importance of Colombia within the larger global framework of GlaxoSmithKline (GSK)? Michael Sean Reilly:…
Novo Nordisk Brazil Diabetes affects an estimated 6 million Brazilians, a figure which is expected to double by 2025, in line with many other developing nations. Like many other “rich-country” diseases, there is a tendency for its sudden prevalence to result in less-than-adequate treatment profiles. What have you observed here in Brazil? The…
BESINS HEALTHCARE Brazil Besins finally arrived in Brazil in 2010. In addition to introducing the company to the market, would you also elaborate on the strategic motivation behind this decision? Besins Healthcare is a pharmaceutical company specialized in the development and worldwide diffusion of innovative drugs and food supplements for the well-being of…
Bomi Farma Much has changed at Bomi since we last met in 2007. At that time, you were launching your new facilities, with 72,000 square metres of built area, 14 metres free floor height, 108 docks, and 65,000 pallet capacity – it was a very exciting time. What have been the most…
Kolbe You have been working at Kalbe for 38 years, and as President Director for 11 years. What has it been like to see the firm transform from a company based in a garage in Tanjung Priok, to the leading pharmaceutical company in the country? From the company’s founding days, there…
Chiesi Pharmaceuticals BV The Dutch affiliate of Chiesi was established in 2007 when many changes were occurring in the local industry. The new healthcare system policy went into effect and the market was shifting towards a cost-containment structure. What drove Chiesi’s decision to start-up in the Netherlands? Our respiratory product, Foster, was one…
Bristol-Myers Squibb Brazil Two days ago, the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan against chronic diseases for when the UN next addresses the General Assembly in September. What would be your suggestions? If…
Boehringer Ingelheim Brazil You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three years, my assignment was to open this company and to integrate it more with Brazil. We have a quite enlightened…
Eli Lilly do Brasil An important topic in Brazil is access to drugs. In recent interviews we have spoken about a third of MS patients being treated, or 10% of hypertensives having their condition under control. With your predecessor Mr. Crupi in 2007 we compared the situation in Brazil to Canada, one of his…
AstraZeneca Brazil What have been some of the recent milestones and achievements contributing to AstraZeneca Brazil’s status as the country’s fastest growing MNC? What happened in the last 10 years was a very productive combination of excellent products being worked by talented people with the right level of investment. This is what…
See our Cookie Privacy Policy Here